Camilla Hansen
Président chez Aloop Therapeutics ApS
Profil
Camilla Petrycer Hansen is currently the Chairman at Aloop Therapeutics ApS, the Director at Hoba Therapeutics ApS, and the Director at LimmaTech Biologics AG.
She previously worked as the Principal at Novo Seeds and Novo Holdings Ltd.
Additionally, she has experience as the Director at Centauri Therapeutics Ltd.
Dr. Hansen holds a graduate and doctorate degree from the University of Copenhagen.
Postes actifs de Camilla Hansen
| Sociétés | Poste | Début |
|---|---|---|
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01/06/2018 |
Novo Holdings Ltd.
 Novo Holdings Ltd. Financial ConglomeratesFinance Part of Iron Mountain, Inc., Novo Holdings Ltd. functions as an investment holding British company. The company is based in London, UK. | Corporate Officer/Principal | - |
Hoba Therapeutics ApS
 Hoba Therapeutics ApS BiotechnologyHealth Technology Hoba Therapeutics ApS engages in research and experimental development in biotechnology. The firm’s purpose is commercialization of pharmaceuticals and biotechnology services. The company was founded on November 28, 2016 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Aloop Therapeutics ApS
 Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022. | Président | - |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 09/10/2023 |
Anciens postes connus de Camilla Hansen
| Sociétés | Poste | Fin |
|---|---|---|
Centauri Therapeutics Ltd.
 Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Camilla Hansen
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Finance |
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
Novo Holdings Ltd.
Novo Holdings Ltd. Financial ConglomeratesFinance Part of Iron Mountain, Inc., Novo Holdings Ltd. functions as an investment holding British company. The company is based in London, UK. | Finance |
Hoba Therapeutics ApS
Hoba Therapeutics ApS BiotechnologyHealth Technology Hoba Therapeutics ApS engages in research and experimental development in biotechnology. The firm’s purpose is commercialization of pharmaceuticals and biotechnology services. The company was founded on November 28, 2016 and is headquartered in Copenhagen, Denmark. | Health Technology |
Aloop Therapeutics ApS
Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022. | Health Technology |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
